Clinical trials: Cancer of the Esophagus
Esophageal Cancer
Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer
This study is designed to determined the feasibility and safety in advanced esophageal cancer treated with docetaxel and cisplatin cocurrent chemoradiotherapy.
- Trial name
- NCT01640860
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Chonnam National University Hospital
Esophageal Cancer
S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00659113
- Testing
- cisplatin, tegafur-gimeracil-oteracil potassium, cytology specimen collection procedure
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Esophageal Cancer
Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Depending upon the cancer stage, esophageal cancer can be treated with surgery, chemotherapy, radiation therapy, or a combination of these modalities.
- Trial name
- NCT03335813
- Testing
- Endoesophageal Brachytherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer, Lung, Cancer of Esophagus
Radiogenomics in Aerodigestive Tract Cancers
Aerodigestive tract cancers are common malignancies. These cancers were ranked to be top-ten cancer-related deaths in Taiwan. Although many new target therapies and immunotherapies have emerged, many of the treatment eventually…
- Conditions
- Cancer, Lung, Cancer of Esophagus, Cancer of Head and Neck
- Trial name
- NCT04314349
- Where
- Taiwan
- Volunteers
- 139 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Esophageal Neoplasms
The Predictive Value of CT-PET in Esophageal Cancer
A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative…
- Trial name
- NCT02385604
- Where
- Ireland
- Volunteers
- 250 people
- Sponsor
- St. James's Hospital, Ireland
Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia, AI-Based Dissection Trajectory Prediction System
- Trial name
- NCT07757906
- Testing
- AI-based Dissection Trajectory Prediction System (ADTPS), Conventional ESD Procedure
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Qilu Hospital of Shandong University
Esophageal Cancer, Surgery
Prehabilitation for Esophageal Resection Surgery
Consenting patients scheduled for esophageal resection surgery will be randomized to receive standard nutrition counseling (including nutritional supplements as needed) or standard nutrition counseling and exercise 4 weeks before…
- Trial name
- NCT01666158
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Franco Carli
Esophageal Squamous Cell Carcinoma
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention…
- Trial name
- NEEDS (NCT04460352)
- Testing
- Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Esophagectomy
- Where
- 12 sites in Canada, Ireland and 3 more
- Volunteers
- 1,020 people
- Sponsor
- Karolinska University Hospital
Esophageal Cancer, Gastric Cancer
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004127
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Esophageal Cancer, Gastric Cancer
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin…
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00911820
- Testing
- Bevacizumab, Cisplatin, Irinotecan
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Cancer of Pancreas
Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory.
- Conditions
- Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Esophagus
- Trial name
- NCT03347162
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Esophageal Cancer
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
Definitive chemoradiation is the standard treatment for locally advanced esophageal cancer. NCCN (National Comprehensive Cancer Network) recommends radiation dose of 50-50.4 Gy as the definitive radiation dose for esophageal…
- Trial name
- NCT02850991
- Testing
- High-dose, Standard-dose
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Carcinoma
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is definitive concurrent chemoradiotherapy (CCRT).
- Trial name
- NCT07034118
- Testing
- Proton radiotherapy, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Carcinoma
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）
The prognosis and safety of patients with locally advanced esophageal squamous cell carcinoma were compared with different neoadjuvant therapy modes in multi-cancer centers in China
- Trial name
- NEO-EC (NCT06828718)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hebei Medical University Fourth Hospital
Barrett Esophagus, Gastroesophageal Reflux
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease…
- Trial name
- NCT01129778
- Testing
- Zegerid (proton pump inhibitor), Bravo pH monitoring
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Esophageal Neoplasms
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
To determine the activity and efficacy of the schema specified as dose regimen To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
- Trial name
- NCT00259402
- Testing
- Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.